Showing 2931-2940 of 5085 results for "".
Who's Responsible for Your Receivables?
https://practicaldermatology.com/topics/general-topics/PD0109_02-php/22889/When it comes to timely collection of payments, different staff members have important responsibilities.- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- P&G Ventures Reintroduces Bodewell Line for Eczema and Psoriasishttps://practicaldermatology.com/news/pg-ventures-reintroduces-bodewell-line-for-eczema-and-psoriasis/2461098/P&G Ventures is reintroducing Bodewell, a line of skin care products for people with eczema and psoriasis. Bodewell’s new eczema and psoriasis lines feature actives like Colloidal Oatmeal and Salicylic Acid along with essential moisturizers and a novel botanical blend ca
- Christopher G. Bunick, MD, PhD, Receives the American Acne and Rosacea Society's 2023 Research Scholar Awardhttps://practicaldermatology.com/news/christopher-g-bunick-md-phd-receives-american-acne-and-rosacea-society-announces-2023-research-scholar-award/2461962/Christopher G. Bunick, MD, PhD, has received The American Acne and Rosacea Society’s (AARS) 2023 Research Scholar Award. Dr. Bunick is an Associate Professor of Dermatology at Yale University School of Medicine and a member of the Practical Dermatology magazine editorial board.</
- P&G to Unveil Improved Opte Precision Skincare System at CES 2020https://practicaldermatology.com/news/pg-to-unveil-improved-opte-precision-skincare-system-at-ces-2020/2460243/P&G Ventures, the startup studio within Procter & Gamble, is slated to showcase the Opte Precision Skincare System, the first personalized handheld inkjet printer to instantly make the appearance of skin's hyperpigmentation disappear and fade spots over time, at CES 2020. CE
- Revance Therapeutics Appoints Roman G. Rubio, MD, MBA, as Senior Vice President of Clinical Developmenthttps://practicaldermatology.com/news/revance-therapeutics-appoints-roman-g-rubio-md-mba-as-senior-vice-president-of-clinical-development/2458649/Revance Therapeutics, Inc. has named Roman G. Rubio, MD, MBA Senior Vice President of Clinical Development. Dr. Rubio will report to Chief Operating Officer Abhay Joshi, and will lead the company’s clinical development team, focusing on further accelerating the advancement of Reva
- Delgocitinib for CHE Gains EC Approval, FDA NDA Acceptancehttps://practicaldermatology.com/news/delgocitinib-che-gains-ec-approval-fda-nda-acceptance/2468259/Delgocitinib cream 20 mg/g (2%) reached major milestones in both the United States and Europe, LEO Pharma Inc. announced. The US Food and Drug Administration (FDA) accepted a filing for a New Drug Application (NDA) for LEO Pharma’s AnzupgoÒ for the treatment of adults with moderate-to-seve
- Study Explores Potential of GLP-1 Agonists for Skin Disease Managementhttps://practicaldermatology.com/news/study-explores-potential-glp-1-agonists-skin-disease-management/2468016/Recent research highlights the potential of GLP-1 agonists in managing dermatological conditions such as psoriasis, hidradenitis suppurativa, acanthosis nigricans, and Hailey-Hailey disease, especially in patients with obesity or type 2 diabetes mellitus (T2DM). Glucagon-like peptide-1 (G
- DISCREET: Apremilast Effective for Genital Psoriasis for Treatment Nonrespondershttps://practicaldermatology.com/news/discreet/2462239/Apremilast was efficacious in reducing the symptoms of genital psoriasis (G-PsO) in patients who didn't respond to topical treatments or who were not adequately controlled by topical therapy, new research indicates. DISCREET aimed to evaluate the efficacy and safety of apremil